This year has seen a number of tech giants like Snap, Cloudera, and Roku, make the jump into public markets. Meanwhile, one lesser-known company, Alteryx, which made its IPO in March, is quietly raking in the gains. Dean Stoecker, CEO of Alteryx, an analytics platform for enterprises, joined Cheddar to explain what’s clicking for his company.
The company's stock is up significantly from its IPO price of $14 a share. Stoecker explains how Alteryx's uncoventional path to IPO set the analytics company up for a strong start. He says raising money is a weakness, not a strength. That's why it took him 14 years to take in investments, and 20 years to move into the public spotlight.
Stoecker says Alteryx is bringing the thrill back to analytics. The company has a giant list of customers, including Walmart and Boeing. The CEO breaks down how Alteryx is looking to change the way these companies interpret data.
Joe Spector, founder of Dutch and Hims & Hers co-founder, joins us to discuss how telehealth is transforming pet care—and what’s next for modern vet medicine.
Exclusive: Behr’s Andy Lopez reveals how ChatHUE, a bold collaboration with Google, is using AI to transform how we explore, choose, and connect with color.
Brian Vendig, President & CIO of MJP Wealth Advisors, joins to break down Q2 bank earnings and what they signal for markets, investors, and the economy ahead.
Are Gen Z and Millennials done with alcohol? Bacardi's Tony Latham breaks down trends, new preferences, and insights from the 2025 Cocktail Trends Report.
Comscore’s Paul Dergarabedian breaks down the battle of summer blockbusters, from Superman to Jurassic World and Fantastic Four and what it means for studios.
VENU CEO JW Roth breaks ground on a 20,000-seat, state-of-the-art amphitheater in Texas—part of a $300M public-private expansion to redefine live music.
Despite healthcare spending cuts, medtech stocks like Edwards Life Sciences, Stryker, and Boston Scientific are rising, especially those serving older pati
